New Triple-Threat attack on tough lung cancer

NCT ID NCT06898957

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

Summary

This early-stage trial is testing a new combination of three drugs—tarlatamab, YL201, and an anti-PD-L1 drug—for people with extensive stage small cell lung cancer. The main goal is to see if this combination is safe and tolerable for patients. It will also measure how well the treatment shrinks tumors and controls the cancer's growth.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alexandra Hospital
RECRUITING

Athens, 11528, Greece
Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
RECRUITING

Milan, 20162, Italy
CHU de Quebec Hopital de l Enfant Jesus
RECRUITING

Québec, Quebec, G1J 1Z4, Canada
Centre Leon Berard
RECRUITING

Lyon, 69373, France
City of Hope Orange County Lennar Foundation Cancer Center
RECRUITING

Irvine, California, 92618, United States
Cleveland Clinic Foundation
RECRUITING

Cleveland, Ohio, 44195, United States
Clinexpert Kft Bugat Pal Korhaz
RECRUITING

Gyöngyös, 3200, Hungary
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
European Interbalkan Medical Center
RECRUITING

Thessaloniki, 57001, Greece
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Fujian Cancer Hospital
RECRUITING

Fuzhou, 350011, China
Gustave Roussy
RECRUITING

Villejuif, 94805, France
Henry Dunant Hospital Center
RECRUITING

Athens, 11526, Greece
Hospital Universitari Vall d Hebron
RECRUITING

Barcelona, Catalonia, 08035, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Puerta de Hierro Majadahonda
RECRUITING

Majadahonda, Madrid, 28222, Spain
Hospital de la Santa Creu i Sant Pau
RECRUITING

Barcelona, Catalonia, 08041, Spain
Iatriko Diavalkaniko Thessalonikis
RECRUITING

Thessaloniki, 57001, Greece
Institut Bergonie
RECRUITING

Bordeaux, 33000, France
Institut Universitaire du Cancer Toulouse Oncopole
RECRUITING

Toulouse, 31059, France
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
RECRUITING

Meldola (FC), 47014, Italy
Istituto di Candiolo Fondazione del Piemonte per l Oncologia IRCCS
RECRUITING

Candiolo to, 10060, Italy
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Sanford Oncology Clinic and Pharmacy
RECRUITING

Sioux Falls, South Dakota, 54104, United States
Sanford Roger Maris Cancer Center
RECRUITING

Fargo, North Dakota, 58122, United States
Semmelweis Egyetem
RECRUITING

Budapest, 1083, Hungary
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Severance Hospital Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea
Shandong Cancer Hospital
RECRUITING

Jinan, Shandong, 250117, China
Siteman Cancer Center
RECRUITING

St Louis, Missouri, 63110, United States
Swedish Medical Center
RECRUITING

Seattle, Washington, 98104, United States
Universitaetsklinikum Essen
RECRUITING

Essen, 45147, Germany
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, 611135, China
Yale New Haven Hospital
RECRUITING

New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.

SMALL CELL LUNG CANCER